Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12219942 | 0.89 | PABPC1 (0.45) | GPR35RECQLMAPTCYSLTR2CYSLTR1 | |
| SCHEMBL12220086 | 0.87 | GPR35 (0.48) | GPR35GRM1CYSLTR2CYSLTR1PIM1 | |
| SCHEMBL12220125 | 0.86 | MAPT (0.52) | GPR35RECQLGRM1MAPTPIM1 | |
| SCHEMBL12220072 | 0.86 | SMN1; SMN2 (0.49) | GPR35MAPTCYSLTR2CYSLTR1PABPC1 | |
| SCHEMBL12220135 | 0.85 | GPR35 (0.48) | GPR35GRM1CYSLTR2CYSLTR1GPR55 | |
| SCHEMBL12220021 | 0.85 | GPR35 (0.48) | GPR35RECQLGRM1MAPTCYSLTR2 | |
| SCHEMBL12220116 | 0.85 | GPR35 (0.48) | GPR35RECQLGRM1MAPTCYSLTR2 | |
| SCHEMBL12220050 | 0.85 | HSD17B10 (0.56) | GPR35MAPT | |
| SCHEMBL12220013 | 0.84 | GPR35 (0.43) | GPR35CYSLTR2CYSLTR1 | |
| SCHEMBL12219989 | 0.83 | GPR35 (0.53) | GPR35MAPTCYSLTR2CYSLTR1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2342188-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GPR35 866/4885RECQL 916/4885GRM1 2898/4885 |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GPR35 627/4885RECQL 968/4885GRM1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.